Annoucements - Business
We are pleased to announce the Joint Venture of Naari & Wellesta for Singapore as NaariEsta Pte Ltd.
Effective from 27th Nov 2020

Naari Pte Ltd & Wellesta Holdings Pte Ltd are pleased to announce its joint venture for Singapore as NaariEsta Pte Ltd. Naari will be investing 65% and Wellesta would invest 35% in the joint venture. This will be a vertically integrated, women’s health focused company: NaariEsta Pte Ltd, operating in Singapore and Brunei markets.

Naari Pte is headquartered in Singapore and has development and manufacturing capabilities for fermentation intermediates, active pharmaceutical ingredients and finished dosage forms. Apart from a vast portfolio of generic APIs and FDFs, Naari has other innovative products at various stages of development and clinical trials. Naari’s mission is to have a comprehensive product portfolio that serves the needs of women throughout their lives – from puberty, through pregnancies, menopause and post-menopause.

Wellesta is a company headquartered in Singapore and its main specialty is in Marketing, Brand Management, Sales & Operations with world-class standards in its business approach and compliance. Its focus is on the Asia Pacific market to provide pharmaceutical and medical devices and consumer healthcare products. Wellesta aims to be a valued partner to healthcare companies in serving the community in Singapore and the Asia Pacific with a cost-effective and wide range of pharmaceutical and healthcare products, with women-care being one of the focus areas. The joint-venture offers win-win synergies for both companies.

The joint venture between the two companies provides opportunities for synergy, with Naari bringing in products from both the prescription and the OTC line, as well as medical devices and other products. Wellesta’s comprehensive understanding of the market aims to provide the right platform for the products to expand towards to greater heights. The joint venture will be a union of the two companies offering a comprehensive women's health portfolio with an aim to provide products and be a partner in the journey of overall wellness of women in Singapore. With niche and diversified product portfolio, NaariEsta would have access to women's healthcare market in Singapore of about USD 20 million and will start realizing the revenues from April'2021 onwards.

Both Wellesta and Naari operate based on the principles of High Integrity, Value-added partner and Full Transparency for our principals. With this, NaariEsta’s mission to serve women’s needs by providing high-quality healthcare products and services at an optimum price will be achieved through this joint venture which will be driven by our commitment, in-market expertise and efficient enactment.
We are pleased to announce our Strategic Business Partnership for Middle East & North Africa with Cureleads, a company headquartered in Dubai & Beirut.
Effective from 9 Sep 2020

We are pleased to announce the collaboration of Wellesta and Cureleads.

Wellesta is a company headquartered in Singapore and support Healthcare companies to expand their reach of products for larger access to patients & brand building by way of offering sales, marketing & distribution. It also helps smaller MNC’s & Biotech companies as launch pad for their products to be launched in Asia Pacific. Wellesta is led by Industry Proven leaders at HQ & Country level.

Cureleads is a company headquartered in Dubai & Beirut and aspires to transform patient’s lives by leading the path to cure specialty and rare diseases. It is founded by highly profiled industry leaders regionally and globally.

Cureleads is involved in the business of distribution and marketing of medicinal and pharmaceutical products in Middle East, Dubai & North Africa.

Wellesta is in the business of marketing, brand creation, sales & distribution of medicinal and Healthcare products with focus on Asia Pacific.

With this collaboration both companies can help companies to get coverage across Asia Middle East & Africa (AMEA) geographies. Both companies operate on the principles of High Integrity, Value added partner & Full transparency for our Principals. This alliance will help companies get a partner which provides excellent reach in AMEA countries.

Apart from this, both companies will also provide bilateral support for each other through medical talks, health fairs, newsletters and websites or such other media. They will carry out joint research on the demographics, risk profiles and care needs of the population in both territories from time to time.

Thus, Wellesta’s goal to support and provide high quality healthcare products & services at optimum price to improve health access to masses, and Curelead’s goal to lead the transformation of patients’ lives & curing speciality diseases will be accomplished through this collaboration in Asia Middle East & Africa. Our focus would be driven through our dedicated efforts, strong in-market experience, best-in class capabilities, determination and excellent execution.
We are pleased to announce the appointment of Mr. Norman Phua as OTC Product Manager for Singapore.
Effective from 10th May 2021

Mr. Norman Phua has been appointed as OTC Product Manager for Singapore with effect from 10 May, 2021.

Norman brings with him over 10 years of brand and marketing experience from the FMCG and Consumer Goods industry, working across organizations such as Nestle, Fonterra, F&N and Tefal. He has managed and grown various brands under his care though new product launches, brand building activations and profitability management.

Norman holds a Bachelor of Business Management degree from the Royal Melbourne Institute of Technology.

At Wellesta, we see opportunity for good growth within the Singapore Pharmaceutical & OTC industry with addition of Norman to the Wellesta team. We welcome him to our Wellesta family and look forward to his dedicated contribution in the overall management and growth of Wellesta business in Singapore.

Norman will report to Mr. Paul Lim, Country Head for Singapore, and OTC Lead for Singapore, Philippines and Indonesia.
We are pleased to announce the appointment of Dr. Tan Wei Liang as Associate Product Manager for Singapore.
Effective from 1st Oct 2020

Dr. Tan Wei Liang has been appointed as Associate Product Manager for Singapore with effect from 1st October, 2020.

Prior to joining Wellesta, Dr. Tan worked at AstraZeneca where he helped launched Immuno- oncology into the Singapore Market. Dr. Tan started his pharmaceutical career in medical affairs at Bayer where he was involved in various medical excellence and governance projects for the Asia Pacific region and was part of the team reviewing Patient Support Programs across the markets.

Dr. Tan is highly passionate about innovation and possesses both commercial and medical affairs experience in the pharmaceutical industry. He completed his Ph.D. in Biological Sciences with the Nanyang Technological University in Singapore.

We at Wellesta see opportunity for good growth within Singapore Pharmaceutical & OTC industry with addition of Dr. Tan to Wellesta team. We welcome Dr. Tan Wei Liang to our Wellesta family and look forward to his dedicated contribution in the overall management and growth of Wellesta business in Singapore.

Dr. Tan will report to Paul Lim, Country Head for Singapore and OTC Lead for Singapore, Malaysia and Indonesia.
We are pleased to announce the appointment of Mr. Vincent Chua as Key Account Manager, OTC for Singapore.
Effective from 1st Aug 2020

Mr. Vincent Chua has been appointed as Key Account Manager, OTC for Singapore business with effect from 1st August, 2020.

Mr. Chua comes with deep industry knowledge and in-market experience. His previous portfolio includes various sales management roles with Zuellig Pharma and Pfizer where he had built and lead a team of merchandisers and promoters to launch VMS products and achieved strong double-digit sales growth in the VMS categories.

Mr. Chua is highly motivated and comes with over 12 years of experience in the pharmaceutical and consumer healthcare over-the-counter (OTC) industry where he had built and maintained a healthy relationship with customers in both Modern and General Trade. He had exposure to regional coverage that extended to Malaysia and Brunei.

Mr. Chua holds a Bachelor of science degree - Business Management from the University of Bradford. Mr. Vincent will report to Mr. Paul Lim, Country Head for Singapore, and OTC Lead for Singapore, Malaysia and Indonesia.

We at Wellesta see opportunity for good growth within Singapore Pharmaceutical & OTC industry with addition of Mr. Vincent Chua to Wellesta team. We welcome Mr. Vincent Chua to our Wellesta family and look forward to his dedicated contribution in the overall management and growth of Wellesta business in Singapore.
We are pleased to announce the appointment of Mr. Paul Lim as Country Head for Singapore and OTC Lead for Singapore, Malaysia and Indonesia.
Effective from 1st Mar 2020

Mr. Paul Lim has been appointed as Country Head for Singapore and OTC Lead for Singapore, Malaysia and Indonesia with effect from 1st March, 2020.

Mr. Lim previously worked at Church & Dwight where he launched and achieved market leadership in numerous countries in the Nasal care and VMS categories as OTC Lead - Asia Pacific. Mr. Lim is a highly motivated and experienced commercial leader with over 18 years of experience in the pharmaceutical and consumer health industry across Asia Pacific.

With his expertise and robust experience, he has held various key commercial roles in multinational companies such as Pfizer, Alcon and Church & Dwight. He also enabled Alcon Singapore to extend its leadership in the pharmaceutical franchise of ophthalmology as Business Unit Head.

He holds Bachelor of Business degree from the University of Central Queensland and has completed his coursework for Global MBA from University of London.

We at Wellesta see good opportunity for Singapore Pharma & OTC Market and in other SE emerging markets. With addition of Mr. Lim to Wellesta team, would help driving opportunities and meet the Vision and Mission of our company.

Mr. Lim will report to Milan Paleja, Director of Wellesta Healthcare Singapore Pte Ltd & also Chairman & MD of Wellesta Group.

We welcome Mr. Paul Lim, who is now based in Singapore, to our Wellesta family. We look forward for his dedicated contribution in the overall management and growth of Wellesta business in Singapore as well as being the Lead for the OTC Businesses in Malaysia and Indonesia.
No News Found